Skip To Content


Open conversations, knowledge sharing, and fresh ideas promote positive change and transparency

Thought leadership

Read more

Leader Perspective

Read more


Read more


Read more

Our latest blog posts, articles and podcasts 

Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.

June 12, 2024 · Public Policy & Regulatory Affairs Team
May 29, 2024 · Public Policy & Regulatory Affairs Team
Robert Wilson, president of, talks to the Policy Guys about the diverse and extended course offerings in the realm of workers’ comp available on this innovative training platform. Listen in to boost your understanding as well as your street cred. Read more...
May 22, 2024 · Public Policy & Regulatory Affairs Team
Oklahoma expands PTSD coverage for first responders with treatment limits, model drug pricing reporting law amended to exclude work comp and auto, model drug formulary law up for review, Virginia requires patient counseling with opioid prescribing, and several states reviewing changes to their medical rules. Read more...
May 16, 2024 · Public Policy & Regulatory Affairs Team
As a result of DEA plans to reclassify marijuana from a Schedule I to a Schedule III drug, more states may decide to reimburse injured workers for its prescribed use and include it in their workers’ comp fee schedules. Clients are advised to follow future developments of this initiative on the federal and state level. Read more...
May 13, 2024 · Medicare Insights Team
On April 16, 2024, the Center for Medicare and Medicaid Services (CMS) hosted a webinar to discuss Workers Compensation Medicare Set-Asides (WCMSAs) and Civil Money Penalty (CMP) impacts. Our latest blog gives a recap of the webinar and the follow up Q&A session held on April 25. Read more...
May 07, 2024 · Clinical Team
On May 4, 2024, the U.S. Food and Drug Administration (FDA) reported that Breckenridge Pharmaceutical, Inc (Breckenridge) issued a retail level recall of duloxetine delayed-release capsules. Read more...
     Next >>
Page 1 of 7